Trial Profile
An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Epicatechin (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacodynamics; Proof of concept
- 15 Jan 2019 Status changed from recruiting to completed.
- 06 Jun 2018 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.
- 06 Jun 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Oct 2018.